Introduction
Lung cancer is the leading cause of cancer-related death in both the United States and major industrialized nations (Greenlee et al., 2001) . Despite extensive eorts made in development of diagnostic and therapeutic methods the past three decades, the overall 5-year survival rate remains low (Parkin et al., 1999) . It is due mainly to the lack of eective methods of diagnosing lung cancer early enough, for cure and regimens to suciently prolong quality of life of patients with advanced stages of lung cancer. In current practice, only 15% of patients with lung cancers are diagnosed at a localized stage and about 50% ®ve-year survival rate is expected for this population. Once tumors spread out of the local region, the outcome is extremely poor.
Development of lung cancer requires repeated insult of carcinogens, mainly from tobacco smoke, in lungs over a long period of time. The process so called carcinogenesis takes a few decades and results in accumulation of multiple molecular abnormalities in cells, which is the basis of malignant transformation and tumor progression. Evidences have emerged to demonstrate that genetic abnormalities occur in the early carcinogenic process in lungs of chronic smokers and certain abnormalities may persist for many years after smoking cessation (Mao et al., 1997; . A number of genetic and molecular alterations, such as mutations in the p53 tumor suppressor gene (Tomizawa et al., 1999) and K-ras proto-oncogene (Graziano et al., 1999) , promoter hypermethylation of the p16 tumor suppressor gene (Belinsky et al., 1998) , and loss of heterozygosity (LOH) in multiple critical chromosome regions (Takamochi et al., 2001; Zhou et al., 2000) , have been frequently identi®ed in early stage lung cancers. A number of investigators have been exploring the possibility of using these alterations as biomarkers in lung cancer early detection and risk assessment. With the completion of human genome mapping and advances in high-throughput technologies, the discovery of molecular alterations in the carcinogenic process is accelerating. A substantial eort is now undertaken to conduct large-scale co-operative discoveries and validations of biomarkers for early cancer diagnosis, such as the Early Detection Research Network (EDRN) sponsored by National Cancer Institute in the United States. It is anticipated that molecular marker-based novel diagnostic strategies will be developed and emerged into clinical practice to augment current inecient tools of diagnosed patients with early stage lung cancer.
Molecular abnormalities in early lung tumorigenesis
From diagnostic or screening point of view, any consistent abnormality whether it contributes to process of malignant initiation and progression or is only a consequence of such process may be used as a marker as far as it occurs early in tumorigenesis and can be detected speci®cally in a specimen from individuals with clinical or sub-clinical lung cancers. The search for such abnormalities has been intensive in the past decade and accelerated recently due to the completion of human genome project and rapid Oncogene (2002) 21, 6960 ± 6969 advances in high-throughput experimental methods. A number of abnormalities have been identi®ed and can be classi®ed into four major categories: (1) genetic abnormalities which are usually clonal and in reversible; (2) epigenetic abnormalities which are often clonal but may be reversible under certain conditions; (3) abnormal presence or amount of gene products which may be variable under dierent conditions; and (4) abnormal auto antibodies.
Genetic abnormalities
A number of genetic alterations have been identi®ed in lung cancers and even in morphologically normal tissues with chronic carcinogen insult. Primary lung cancer can be classi®ed into two major subtypes, i.e., small cell lung cancer and non-small cell lung cancer based on morphology characteristics. The later type can be further classi®ed into squamous cell carcinoma, adenocarcinoma, and large cell carcinoma etc. These subtypes of lung cancers have distinct clinical presentation and respond dierently to therapies. It is not surprising that these tumors may contain distinct pro®les of genetic abnormalities although certain abnormalities may be shared in all the tumor types. From diagnostic point of view, it is important to understand not only the common abnormalities but also the dierences among the subtypes.
Mutations of K-ras proto-oncogene is the most commonly mutated gene in the ras gene family, representing approximately 90% of the mutations identi®ed. In lung cancer, mutations in K-ras gene are found in about 20% of the tumors with mutation hot spot at codon 12. However, the mutation frequencies are signi®cantly dierent among histological subtypes of lung cancer. Most of the K-ras mutations are detected in lung adenocarcinomas, accounting for about 30% of these tumors, but rare in other subtypes (Salgia and Skarin, 1998) , suggesting mutations in K-ras may be important in development of adenocarcinoma of the lungs. Since K-ras mutations can transform cells (Niklinski et al., 2001; Lacal et al., 1986) and have also been observed in early stage lung tumorigenesis (Westra et al., 1996) , they are considered important in tumor initiation or early progression.
The p53 gene encodes a nuclear protein which involves in the cell cycle control, DNA repair, cell dierentiation, genomic stability, and programmed cell death (Vousden, 2000; Vogelstein and Kinzler, 1992) . Mutations of the p53 tumor suppressor gene play an important role in lung tumorigenesis and occur in about 50% of NSCLC and more than 70% of SCLC (Harris and Hollstein, 1993; Tseng et al., 1999a) . Most of the mutations identi®ed in lung cancers are missense mutations. The half-life of the wild-type p53 protein is short, which makes the protein undetectable in normal cells. However, the half-life of mutant p53 proteins is often prolonged. The mutant proteins, therefore, may be accumulated in nucleus and become detectable. Although not always re¯ecting a mutation status, positive p53 staining can be detected in about 50% of lung cancers by immunohistochemistry (IHC) (Carbone et al., 1994; Eerola et al., 1997; Nishio et al., 1996) . However, it should be noted that although most of tumors with missense mutations of p53 may be positively stained, tumors with nonsense mutations, deletions or insertions in the coding regions, and splicing abnormalities may be negative in the IHC analysis. Frequent accumulation of p53 protein has been noticed in preneoplastic bronchial lesions, such as bronchial metplasia, dysplasia, and carcinoma in-situ (Ponticiello et al., 2000) .
Abnormalities of chromosome numbers and genetic composition within chromosomes are hallmarks of malignancies. Recent development of technologies makes analysis of chromosome alterations in clinical materials easier and more reliable. Fluorescent in situ hybridization (FISH) has been widely used for chromosome deletions and ampli®cations at speci®c regions in cells or even paran embedded tissue sections. Comparative genomic hybridization (CGH) provides an overview of changes in copy number of DNA deletions and ampli®cations (Kallioniemi et al., 1992) . Using CGH, a number of novel chromosome abnormalities have been revealed in lung cancer (Levin et al., 1994) . The development of multi-¯uor FISH technique allows a rapid view of a complex genetic rearrangement as the case in cancer cells (Speicher et al., 1996) . Although chromosome translocation is not often in solid tumors, a chromosome 19 translocation with over expression of Notch3 gene was reported in 6 of 12 lung cancer cell lines tested (Dang et al., 2000) .
Deletion of one of the two chromosome copies at various loci determined by microsatellite markers is probably the most common genetic abnormality in lung cancer cells. There are some hot spots where tumor suppressor genes locate and rates of deletion are high, such as short arms of chromosome 3, 9 and 17 (Tsuchiya et al., 1992; Virmani et al., 1998) . The deletion may occur in the early lung carcinogenic process (Aoyagi et al., 2001; Caballero et al., 2001 ) and has been observed in bronchial epithelium chronically damaged by cigarette smoke (Mao et al., 1997; Wistuba et al., 1997; Hirao et al., 2001) . Microsatellite instability (MA), de®ned as changes in the number of the short-tandem DNA repeats in microsatellites, has been reported in lung cancers (Miozzo et al., 1996; Rosell et al., 1997; Sekine et al., 1997) .
Abnormal protein expression
Abnormal expression of proteins, particularly those overexpressed in cancerous tissues, may oer a potential as diagnostic markers. Both epidermal growth factor (EGF) and its receptor (EGFR) overexpress in more than 60% of NSCLC (Cerny et al., 1986; Gorgoulis et al., 1992; Rusch et al., 1993) , indicating the disruption of the EGF signaling pathway is important in NSCLC. Expression of neuroendocrine factors, including gastrin-releasing peptide/bombesinlike peptides (GRP/BN), and their receptors, are widely expressed in SCLC. Their expression can be detected in almost all SCLC cell lines and one half of the primary SCLC (Richardson and Johnson, 1993) . Thus it is possible that the GRP-receptor autocrine loop is involved in the growth of a proportion of SCLC. A monoclonal antibody, 2A11, against GRP, has been shown to inhibit the growth of SCLC cells in vitro and in vivo (Siegfried et al., 1993; Weber et al., 1988) . GRPR mRNA expression has recently been shown more frequent in female than male non-smokers and more frequent in heavy smokers than short-term smokers suggesting that expression of this gene is activated earlier in women in response to tobacco exposure and may be a factor in the increased susceptibility of women to tobacco-induced lung cancer (Shriver et al., 2000) .
Several cyclins have been found overexpressed in lung cancers. Overexpression of cyclin D1 is found in majority of NSCLC cell lines as a result of abnormal gene ampli®cation. In primary NSCLC tumors, 12 ± 40% of tumors overexpress cyclin D1, while the mechanisms are more complex (Schauer et al., 1994; Mishina et al., 1999) . Cyclin B1 important in G2-Mphase transition has been found overexpressed in 22% of early stage NSCLC and patients whose tumors expressed a high level of cyclin B1 had a signi®cantly shorter survival time compared to those whose tumors expressed a low level of cyclin B1 (Soria et al., 2000) . Overexpression of cyclin E has been reported in more than 50% of NSCLC and also more frequent in squamous cell type (Mishina et al., 2000) .
Abnormal expression of other cell cycle related proteins has also been reported. Cyclin-dependent kinase (CDK4) was found expressed in about 90% of NSCLC and the expression associated with poor dierentiation (Lingfei et al., 1998) . CDKs can be activated by cdc25, which removes inhibitory phosphates from tyrosine and threonine residues. At least three cdc25 genes (cdc25A, cdc25B and cdc25C) have been identi®ed in humans. We analysed primary tumors and corresponding normal lung tissues from patients with NSCLC for relative expression levels of these genes and found that cdc25A was overexpressed in 60% of the tumors and cdc25B in 45% of the tumors, whereas cdc25C was not overexpressed in any of the tumors analysed (Wu et al., 1998) . Abnormal expression of translation initiation factors, such as eIF-4G and eIF-4E, has also been reported in lung cancers (Bauer et al., 2001; Rosenwald et al., 2001) .
Although activation of telomerase alone may not transform a normal cell to a cancer cell, it can substantially prolong the lifespan of cells and therefore permit time for accumulation of molecular damages under insult of carcinogens (de Lange, 1994) . Telomerase activation can be detected in almost all SCLC and 80 ± 85% of NSCLC (Lee et al., 1998) , indicating telomerase reactivation is important in lung tumorigenesis and the major cause of cell immortality. High telomerase activity has been associated with increased cell proliferation rates and advanced pathologic stage in primary NSCLC (Albanell et al., 1997) . Telomerase activity may also be detected in precancerous lesions in lungs (Yashima et al., 1997) , re¯ecting the early involvement of the molecule in lung tumorigenesis. Our recent study has con®rmed the previous observation and further suggests that hTERT, the catalytic subunit of telomerase, may be used as a biomarker to assess potential ecacy of chemopreventive agents .
Epigenetic abnormalities
DNA methylation plays an important role in regulating gene expression in the development. Tumors generally exhibit a global hypomethylation and regional promoter hypermethylation . In early stage lung cancer, aberrant promoter DNA hypermethylation has been observed in a number of genes including several well-characterized candidate tumor suppressor genes including p16 (Nuovo et al., 1999) , DAP-kinase (Tang et al., 2000) , RAR-beta , FHIT (Zochbauer-Muller et al., 2001), RASSF1A (Burbee et al., 2001) , and APC (Usadel et al., 2002) . We and others have recently shown that the aberrant hypermethylation may occur in precancerous stage in carcinogen damaged lungs and may represent a population with an increased risk for development of lung cancer (Belinsky et al., 1998; Soria et al., 2002) . Certain tumor-speci®c antigens such as MAGE gene family may be activated through aberrant promoter hypomethylation in lung carcinogenesis. We recently found that MAGE genes are frequently activated not only in lung cancers but also carcinogen damaged lung epithelial cells .
Splicing abnormalities
Alternative splicing of pre-mRNA is another important regulatory mechanism to control gene expression and to generate proteins with distinct functions. Aberrant pre-mRNA splicing has been noticed in various types of cancers. Aberrant splicing of FHIT candidate tumor suppressor prevents the transcripts from generating a functional protein, which is frequently found in lung cancer and its early tumorigenic process (Tseng et al., 1999b) . We subsequently found that alternative splicing of TSG101, a candidate tumor suppressor gene important in embryonic development ) as a regulator of, and target of, MDM2/p53 circuitry , presents in 89% of SCLC cell lines and 27% of NSCLC cell lines (Oh et al., 1998) . We recently reported that C-CAM, another candidate tumor suppressor gene, also exhibits frequent abnormal splicing patterns in NSCLC (Wang et al., 2000a) . Aberrant splicing may generate proteins with oncogenic properties such as the case of HMD2 (Sigalas et al., 1996) . Aberrant splicing of HMD2 was reported in about 25% of NSCLC (Evans et al., 2001) .
Biomarker-based cancer detection
One of the major reasons which makes early lung cancer diagnosis dicult is the fact that lung is an inner organ and very dicult to be accessed. Current Advances in early diagnosis L Mao clinical diagnosis of lung cancer is mainly based on imaging analysis followed by histology con®rmation. Signi®cant progresses have been made in CT-based lung cancer screening strategy. Low-dose CT appears to greatly improve the likelihood of detection of small non-calci®ed nodules, and thus of lung cancer at an earlier and potentially more curable stage (Henschke et al., 1999) . However, false-positive CT results are common and whether morphologically malignant early tumors have aggressive clinical features is debatable (Patz et al., 2000) . Improved bronchoscopy such as uorescence bronchoscopy may increase sensitivity to reveal small or subtle cancerous and precancerous bronchial lesions (Sutedja et al., 2001) . However, the strategy can hardly become a screening tool for a large population with risk.
Detect molecular alterations in sputum
For biomarker-based screening and diagnosis, access of adequate biological materials is a critical step besides the promise of biomarkers. Sputum is the most commonly utilized biologically material to detect lung cancer cells in a non-invasive manner. Since sputum comes directly from the airway, it may contain cancerous or precancerous cells or abnormal proteins even in a very early tumorigenic stage. However, due to the structure of the airway, particularly the lower airway, each sputum sample may contain only cells derived from part of the airway and therefore is not representative. This contributes in part to the low sensitivity of sputum cytology in lung cancer diagnosis. For a quantitative analysis of secreting molecules, a dilution factor is dicult to be determined in sputum because the amount of sputum may be in¯uenced by many factors. Furthermore, collecting sputum from former smokers or never smokers may be dicult.
About a decade ago, using a PCR-based strategy we demonstrated that cancer cells harboring point mutations of oncogenes such as K-ras and p53 might be detected in sputum of patients with early stage lung cancer (Mao et al., 1994a ). The sputum samples tested were collected from a prospective clinical trial before diagnosis of lung cancers and after curative surgical resection of the tumors in many cases. We were able to show that the test is more sensitive than sputum cytology and chest X-ray because the mutations could be detected up to 18 months before a clinical diagnosis of lung cancer was made (Mao et al., 1994a) .
Because most of K-ras mutations in lung cancers are identi®ed at codons 12 and 13, it is possible to develop simple assays to sensitively detect mutations in samples containing mainly normal cells. Using point-EXACCT (point mutation detection using exonuclease ampli®ca-tion coupled capture technique) for mutations at K-ras codon 12, cancer cells were detected up to 4 years before the clinical diagnosis was made in about 50% patients whose tumors contain such mutations (Somers et al., 1998) . Bronchial alveoli lavage (BAL) has also been used as a biologic material for detection of lung cancer (Scott et al., 1997; Ahrendt et al., 1999; Kersting et al., 2000) . Although the obtaining of BAL requires bronchoscopy, BAL is more representative because a speci®c region of the airway may be sampled. It is note wealthy that K-ras mutations may be detectable in sputum of lung cancer patients whose tumors do not contain such mutations or individuals who has no clinically diagnosable lung cancer (Nakajima et al., 2001) . Such results are not surprising because the K-ras mutations might derive from clinically unidenti®ed small second primary lung cancers or advanced precancerous lesions in individuals with high risk to develop invasive lung cancer. The major shortcoming of the strategy is the low frequency of K-ras mutations in primary lung cancers, meaning only a small fraction of patients with lung cancer may potentially bene®t from the test.
In an earlier study, we showed that microsatellite alterations might be detectable in cytologically negative sputum from patients with lung cancer (Mao et al., 1994b) . Because the vast majority of lung cancers have certain degree of microsatellite alterations, a test for microsatellite alterations may potentially yield a high sensitivity. Miozzo et al. (1996) studied sputum cytology specimens from patients with lung cancer for microsatellite alterations in about 50% of samples analysed. The authors suggested that microsatellite analysis might have a potential application in early diagnosis of precancerous lesions and lung cancer. In a recent study, BAL samples from patients with lung cancer and those without were analysed for microsatellite alterations. Using only four cancer-speci®c markers, the researchers achieved 74% detection sensitivity with 77% speci®city (Liloglou et al., 2001) . One of the important issues is the low speci®city obtained in the study. As microsatellite alterations may be observed commonly in bronchial epithelial cells heavily damaged by carcinogens, it is likely some of these alterations may be detected in sputum from individuals with high risk but not yet with lung cancer. It needs to be determined whether individuals whose sputa show microsatellite alterations will eventually develop invasive lung cancer.
Recent progresses in understanding the role of aberrant promoter methylation have added a new class of molecules in molecular-based cancer detection. In lung cancer, aberrant promoter methylation is frequently found in important tumor suppressor genes such as p16 and FHIT (Merlo et al., 1995; ZochbauerMuller et al., 2001) . In a recent study, Palmisano et al. (2000) utilized a sensitive PCR approach to detect methylated DNA sequences in sputum specimens and found that aberrant methylation of the p16 and/or O6-methyl-guanine-DNA methyltransferase (MGMT) promoters can be detected in 100% of patients with squamous cell lung carcinoma up to 3 years before clinical diagnosis. Interestingly, about 10% of sputum from cancer-free, high-risk subjects also contained the methylated DNA sequences. Although a similar rate of lifetime lung cancer risk is expected in this population, the actual prediction value of the test must be evaluated in prospective studies. Ahrendt et al. (1999) utilized three PCR-based molecular tests, i.e., tumor-speci®c oncogene mutations, CpG-island methylation, and microsatellite alterations, to detect cancer cells in BAL¯uid from patients with resectable NSCLC. The authors found when all the tests combined, cancer cells could be identi®ed in more than half of patients with lung cancer but not in samples without lung cancer. The results are somehow disappointing because the sensitivity is still limited despite multiple advanced technologies have been combined. It may be even harder when sputum is used instead of BAL because of the variable qualities of sputum samples.
An approach combining immunohistochemistry and cytology is continuing in clinical testing with most studies focus on heterogeneous nuclear ribonucleoproteins (hnRNPs) (Mulshine et al., 2000) . Overexpression of hnRNP A2/B1 has shown more sensitive to detect preclinical lung cancer than standard cytomorphology . In the prospective study of tin miners at high risk to develop lung cancer, nRNP A2/ B1 overexpression has an accurate prediction value over 60% compared to merely 10% by cytology . In a subsequent clinical study reported by an independent group, overexpression of hnRNP A2/B1 was measured in BAL and compared with routine diagnostic cytology (Fielding et al., 1999) . The results indicate that hnRNP overexpression was more accurate in detecting evidence of a neoplasia than routine cytological examination. Detection of hnRNPA2/B1 in BAL specimens that contain metaplastic bronchial epithelial cells or cancer cells predicts the presence of a neoplasm with 96% sensitivity and 82% speci®city (Fielding et al., 1999) . However, due to the test is time consuming and requires specially trained personnel for data interpretation, further development of automation and quanti®cation methodologies are necessary in order to apply the technology in clinical practice.
Detect molecular changes in blood
A number of advantages can be counted for using blood as the biological material in early cancer diagnosis, especially in a screening program. It is easy to access and change in volume is minimal in normal conditions, which may allow a quantitative measurement of molecules. However, the use of medications or even dietary may signi®cantly in¯uence contents and make a quantitative assay dicult. Therefore such factors must be considered in designing studies and in data interpretation.
Detect circulating tumor cells Molecular approaches have been used to detect circulating tumor cells. It has been shown for years that circulating tumor cells may be detected even in certain patients with clinical early stage diseases, although the detection is more frequent in patients with advanced diseases. Nevertheless, molecular approaches seem to increase the detection sensitivity. Using reverse transcription-PCR (RT ± PCR), EGFR mRNA-expressing was detected frequently in blood from patients with lung cancer but rare from healthy controls . Expression of other molecules either cancer cell speci®c or cell type speci®c genes such as carcinoembryonic antigen (CEA), cytokeratin 19, neuromedin B receptor, have also been used to detect circulation tumor cells mainly for prognostic assessment (Kurusu et al., 1999; Bessho et al., 2000) .
Detect genetic alterations in serum/plasma Several years ago, Chen et al. (1996) ®rst demonstrated that microsatellite alterations could be frequently detected in serum of patients with SCLC. The surprising ®nding encourages a search for genetic abnormalities in cell free nuclear acid in serum or plasma. In a recent study, Sozzi et al. (2001) analysed circulating DNA in plasma from patients with lung cancer patients and healthy individuals. Not only the alterations were frequent in patients with lung cancer, the variations in DNA level and in microsatellite changes correlated with the clinical status of patients monitored in follow-up care. Allan et al. (2001) studied individuals with symptoms suspicious of lung cancer for LOH in both bronchial biopsy and plasma DNA and found that 12 of the 13 individuals with plasma DNA LOH were subsequently diagnosed with lung cancer. LOH in plasma was also well correlated with LOH in the corresponding tissue biopsies (Allan et al., 2001) . In addition to free DNA in serum/plasma, intact tumor cell-related mRNA may be detectable in such biological materials (Fleischhacker et al., 2001) .
The frequent detect of aberrant promoter DNA methylation in lung cancers, particularly in the early stages, makes such abnormality a possible biomarker in early lung cancer diagnosis. Esteller et al. (1999) conducted a pilot study to determine whether aberrant DNA methylation might be detectable in the serum of patients with lung cancer and found that aberrant methylation could be detected in up to 50% of patients with lung cancer when the promoter regions of four genes were analysed. In a recent study, Usadel et al. (2002) used a quantitative assay to determine the frequency and level of aberrant adenomatous polyposis coli (APC) promoter methylation in primary tumors and paired preoperative serum/plasma samples from lung cancer patients and found that 96% of the primary lung cancer tissues and 47% of the serum/ plasma samples carried detectable amounts of methylated APC promoter DNA but not serum/plasma from healthy controls.
Detect abnormal proteins/peptides Identifying patients with cancer by detecting abnormal serum proteins has always been in the center part of diagnosis theme. Despite of low sensitivity and speci®city, several protein markers are currently used in clinical practice such as CEA. One of the eorts is to identify new secreting proteins which are commonly expressed and speci®c for cancer cells (Pujol et al., 1993; Gure et al., 1998; Bauer et al., 2001; Jang et al., 2001) . Another Advances in early diagnosis L Mao approach is to combine multiple protein markers in order to increase detection sensitivity. However, none of these studies showed a promising result using existing markers (Foa et al., 1999; Tas et al., 2000; Karnak et al., 2001; Salgia et al., 2001) .
Detect auto-antibodies Abnormally expressed proteins and altered protein structures may elicit auto-immunoreaction which generate speci®c antibodies to against the proteins. The presence of anti-p53 antibodies has been frequently found in the sera of patients with lung cancer containing p53 mutations (Iizasa et al., 1998) . In a study with 188 patients with NSCLC, anti-p53 antibodies were detected in over 20% of the patients although it is more frequently detected in patients with more advanced disease (Mitsudomi et al., 1998) . Several other auto-antibodies have recently been identi®ed as potential biomarkers in lung cancer detection. Brichory et al. (2001a) used patients sera to against soluble protein spectrum derived from a lung cancer cell line and demonstrated the frequent presence of anti-glycosylated annexins I and/or II antibodies in patients with lung cancer but not controls. In a recent study, Yamaguchi et al. (2000) analysed a potential humoral response to p40(AIS) (a core domain of AIS products without the transactivation domain) and found anti-p40 antibodies could be detected in the sera of 13/76 (17%) lung cancers. It appears autoantibodies against a single molecule may have limited sensitivity and speci®city in lung cancer detection. Combining multiple targets may improve value of the approach. In a comprehensive study of analysing antinuclear antibodies in patients with lung cancer, Fernandez-Madrid et al. (1999) found by using 12 selected antigens the overall correctly predicted diagnosis was 73%, with 63% sensitivity and 89% speci®city.
Trend and prospective
With the recent progresses in human genetics, functional genomics, imaging technologies, and data analysing methodologies, we may picture a future screening process for diagnosing and treating early stage lung cancer. A sample blood test should be developed to screen high-risk population in a regular basis. The test should be easily performed and ideally a homecare product. It may contain multiple markers to enhance sensitivity and speci®city. After further validation of positive tests using more sophisticated biochip systems, sensitive imaging detection systems may be used to locate early cancers. The results from the sophisticated biochip systems may also provide critical information for molecular classi®cation in order to determine adequate therapeutic strategies. We can also expect the screening system to yield a population who may have precancerous lesions in the process toward an invasive disease and may not have detectable solid mass in lungs. Such population may be targeted for chemoprevention to reduce the incidence of developing invasive lung cancer or signi®cantly delay the process from a precancerous stage to invasive stage. The following issues discussed are critical for the development of a successful screening system.
High-throughput biomarker discovery
Along with the completion of human genome program and the improvement of instrumental technologies, biomarker discovery pace may be accelerated through adoption of high-throughput strategies. Using cDNA microarrays one may identify genes dierentially expressed between normal and tumor cells as well as among dierent tumor cell types (Wang et al., 2000b; Feng et al., 2001; Chen et al., 2001) . Serial analysis of gene expression (SAGE) technology has also been successfully used to identify novel genes or transcripts abnormally expressed in lung cancer (Hibi et al., 1998) . Recently, high-throughput proteomics approached have been utilized in identifying abnormally expressed proteins/peptides in lung cancer cells, serum, and other body¯uid (Oh et al., 2001; Brichory et al., 2001b; Noel-Georis et al., 2001) . These approaches are complementary although some common abnormalities may be identi®ed by dierent approaches (Hibi et al., 1998; Brichory et al., 2001b) . A global approach to identify tumor antigens termed Serological analysis of recombinant cDNA expression libraries (SEREX) has been developed (Chen et al., 1997) and may be used to identify lung cancer speci®c abnormalities in future studies.
Novel diagnostic platforms
Based on current knowledge, it appears no single marker will make a sensitive and speci®c diagnosis of early stage lung cancers. Analysing dozens even hundreds of biomarkers simultaneously may be necessary to achieve a clinically acceptable sensitivity and speci®city for early lung cancer diagnosis. cDNA microarrays have been explored for molecular classi®-cation of human malignancies and shown promising results (Ramaswamy et al., 2001; Pomeroy et al., 2002) . However, the strategy is hardly practicable in early lung cancer diagnosis because it requires adequate biological materials with sucient malignant cells. Development of protein or antibody microarrays may prove to be an important strategy to diagnose early cancers. Once appropriate biomarkers are selected, the strategy may allow a simple high-speed screening of body¯uids such as blood. With the development of advanced analytic computer software, we may achieve an automatic and objective data interpretation with high sensitivity and speci®city. Recent development of protein/peptide pattern recognition in serum sheds light of the novel approach for high-throughput cancer diagnosis. This mass spectrometer based test has shown an extremely high detection sensitivity and speci®city in predicting patients with and without ovary cancer (Petricoin et al., 2002) . Using matrix-assisted laser desorption/ionization-time-of-¯ight mass spectrometry, one may identify distinct protein/peptide patterns in serum between individuals with lung cancer and healthy individuals (Figure 1 ). Once incorporate with powerful analytic tools, hundreds samples may be handled and diagnostic information may be obtained in a few hours.
Acceleration of clinical testing
Once candidate biomarkers are identi®ed and testing platforms are selected, it is very important to conduct rapid clinical trials to validate the discoveries prior to recommending for clinical use. Because the development of lung cancer may take a few decades and the absolute rate of lung cancer development is low even in the high-risk population, it is extremely dicult to conduct a population based prospective study to determine the potential bene®t of a diagnostic product. Extensive eort must be made in building systematic prospective tissue banks together with comprehensive databases and follow-up service. Substantial governmental support in national level is necessary to accelerate the build-up.
Cost and social issues
Economical and social issues may signi®cantly aect the acceptance of an outstanding test by our society. The test should be inexpensive and easily accessible by the general population. However, the potential low pro®t margin may discourage private entities to invest heavily in development and commercialization. Therefore, national policies to favor such industry may be necessary to allow its citizens to bene®t from early cancer screening and control. A successful cancer screening program may identify a population with true high risk to develop lung cancer. Such population may be discriminated such as in job promotion, insurance premier, and marriage. From positive aspect, if lung cancer can be predicted many years prior to invasive stage, the disease may be successfully prevented or cured and, therefore, be viewed as a nonfatal diseases. 
